529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Abstract

The MEDIOLA (NCT02734004) study evaluated the efficacy and safety of olaparib+durvalumab (O+D doublet cohort) and O+D+bevacizumab (O+D+B triplet cohort) in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC). Previous efficacy data showed median progression-free survival (PFS) (95% CI) of 5.5 (3.6–7.5) and 14.7 (10.0–18.1) months (mo) with O+D and O+D+B, respectively (Drew et al, ESMO 2020). We now present the final analysis of overall survival (OS) and disease control rate (DCR) at 56 weeks (wks) in the O+D and O+D+B cohorts.